ArticleJournal of lipid research2011
Group 1B phospholipase A₂ deficiency protects against diet-induced hyperlipidemia in mice.
Article in Journal of lipid research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Hyperlipidemia in membranous nephropathy.Clinical kidney journal · 2026Review
- Identification and verification of biomarkers associated with arachidonic acid metabolism in non-alcoholic fatty liver disease.Scientific reports · 2025Article
- A genome-wide association study identified candidate regions and genes for commercial traits in a Landrace population.Frontiers in genetics · 2024Article
- Inactivation of Group 1B Phospholipase AInternational journal of molecular sciences · 2023Article
- Old but New: Group IIA Phospholipase AMetabolites · 2022Review
- The interaction between brain and liver regulates lipid metabolism in the TBI pathology.Biochimica et biophysica acta. Molecular basis of disease · 2021Article
- The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.Physiological reports · 2021Review
- Secretory Phospholipase A2s in Insulin Resistance and Metabolism.Frontiers in endocrinology · 2021Review
- Rescue of Hepatic Phospholipid Remodeling Defectin iPLA2β-Null Mice Attenuates Obese but Not Non-Obese Fatty Liver.Biomolecules · 2020Review
- sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy.Current medical science · 2020Article
- The Vitamin D Receptor Regulates Glycerolipid and Phospholipid Metabolism in Human Hepatocytes.Biomolecules · 2020Article
- Cytotoxic, Antioxidant, and Metabolic Enzyme Inhibitory Activities ofOxidative medicine and cellular longevity · 2020Article
- A Genome-Wide Association Study on Feed Efficiency Related Traits in Landrace Pigs.Frontiers in genetics · 2020Article
- The role of the small intestine in modulating metabolism and inflammation in atherosclerosis and cancer.Current opinion in lipidology · 2019Review
- Group 1B phospholipase ABiochimica et biophysica acta. Molecular and cell biology of lipids · 2019Review
- Epithelial-Cell-Derived Phospholipase ACell host & microbe · 2017Article
- Enzymatic hydrolysate from velvet antler suppresses adipogenesis in 3T3-L1 cells and attenuates obesity in high-fat diet-fed mice.EXCLI journal · 2017Article
- Liver-specific overexpression of LPCAT3 reduces postprandial hyperglycemia and improves lipoprotein metabolic profile in mice.Nutrition & diabetes · 2016Article
- The Roles of the Secreted Phospholipase AAdvances in immunology · 2016Review
- A new era of secreted phospholipase A₂.Journal of lipid research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Excessive absorption of products of dietary fat digestion leads to type 2 diabetes and other obesity-related disorders. Mice deficient in the group 1B phospholipase A₂ (Pla2g1b), a gut digestive enzyme, are protected against diet-induced obesity and type 2 diabetes without displaying dietary lipid malabsorption. This study tested the hypothesis that inhibition of Pla2g1b protects against diet-induced hyperlipidemia. Results showed that the Pla2g1b(-/-) mice had decreased plasma triglyceride and cholesterol levels compared with Pla2g1b(+/+) mice subsequent to feeding a high-fat, high-carbohydrate (hypercaloric) diet. These differences were evident before differences in body weight gains were observed. Injection of Poloxamer 407 to inhibit lipolysis revealed decreased VLDL production in Pla2g1b(-/-) mice. Supplementation with lysophosphatidylcholine, the product of Pla2g1b hydrolysis, restored VLDL production rates in Pla2g1b(-/-) mice and further elevated VLDL production in Pla2g1b(+/+) mice. The Pla2g1b(-/-) mice also displayed decreased postprandial lipidemia compared with Pla2g1b(+/+) mice. These results show that, in addition to dietary fatty acids, gut-derived lysophospholipids derived from Pla2g1b hydrolysis of dietary and biliary phospholipids also promote hepatic VLDL production. Thus, the inhibition of lysophospholipid absorption via Pla2g1b inactivation may prove beneficial against diet-induced hyperlipidemia in addition to the protection against obesity and diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.